Open Label Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG) for High Risk Stage III/IV Ovarian Cancer

Trial Profile

Open Label Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG) for High Risk Stage III/IV Ovarian Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Acronyms FANG Ovarian
  • Sponsors Gradalis
  • Most Recent Events

    • 28 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 02 Mar 2017 Planned End Date changed from 1 Jan 2018 to 1 Jun 2018.
    • 02 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top